期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉西他滨联合顺铂治疗晚期非小细胞肺癌28例临床观察

下载PDF
导出
摘要 目的观察吉西他滨联合顺铂治疗晚期非小细胞肺癌临床疗效及不良反应。方法28例患者采用吉西他滨1g/m2第1、8、15天给药,顺铂90mg/m2分两天第2、3天化疗。28天为1周期,3周期评价疗效。结果28例可评价疗效和不良反应。初治病例RR为56.3%;复治病例RR为25%。主要不良反应为骨髓抑制。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌有效率较高,不良反应可以耐受。
作者 程劲松
机构地区 南京医科大学附属淮安第一医院
出处 《四川肿瘤防治》 2005年第2期93-94,共2页 Sichuan Journal of Cancer Control
关键词 晚期非小细胞肺癌 吉西他滨 顺铂 临床观察 治疗 不良反应 临床疗效 骨髓抑制 有效率 周期 RR 病例
分类号 R734.2 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1胡毅,冯奉仪.晚期非小细胞肺癌化疗研究现状及展望[J].国外医学（肿瘤学分册）,2002,29(3):197-201. 被引量：45
  • 2Moorsel CJAV, Veeman AM, Mosselman S, et al. Combination chemotherapy studies with gemcitabine[ J]. Semin Oncol, 1997,24(2suppl 17): 17.
  • 3Sandler A,Nemunaitis J,denham C,et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cispatin alone in patients with locally advance or metastatic non-small cell lung cancer[J]. J Clin Oncol,2000,18( 1):122.
  • 4Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advance non-small cell lung cancer:A phase Ⅱ study [J]Clin Oncol, 1997,15 ( 1 ): 297.

二级参考文献20

  • 1Greenlee RT, Murray T, Bolden S, et al. Cancer Statistics [J]. CA Cancer J Clin, 2000,50 (1):7-33.
  • 2Feld R, Abratt R, Graziano S, et al. Pretreatment minimal staging and prognostic factors for non small cell hung cancer [J]. Lung Cancer,1997,17(Suppl 1 ):S3-10.
  • 3Graziano SL, Kern JA, Herndon JE, et al . Analysis of neuroendcrine markersHER2 and CEA before and after chemotherapy in patients with stage Ⅲ A non small cell lung cancer: a Cancer and Leukemia Group B study[J]. Lung Cancer, 1997,21 (3) : 203-211.
  • 4Rafael R , Mark G, Paul G. Adervances in the treatment of non-small cell lung cancer: molecular markers take the stage [J]. Sem Oncol, 2001,1 (28)28-34.
  • 5Cullen MH, Billingham, LJ, Woodroffe CM, et al. Mitomycin, ifosfarnide, and cisplatin in unresectable non-small cell lung cancer:effects on survival and quality of life[J]. J Clin Oncol, 1999,17(10):3188-3194.
  • 6Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group [J]. Anticancer Res, 2000, 20 (3B):2229-2233.
  • 7Wozniak A J, Crowley JJ, Ba Lcerzak SP, et al. Randomized trial comparing cixplatin with a splatin plus vinorelbine in the tzeatment of advanced non-small-cell lung cancer:a Southwest Oncology Group Study [J]. J Clin Oncol, 1998,16(7):2459-2465.
  • 8Sandier A,Nemunaitis J,Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin vesus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer [J]. J Clin Oncol,2000, 18(1) : 122-130.
  • 9von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazarmine plus cisplatin versus cisplatin in advanced non small cell lung cancer:A report of the international CATAPULT study group . Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors[J]. J Ctin Oncol, 2000, 18(6):1351-1359.
  • 10Gatzemeier U, von Pawel J,Gottfried M, et al. Phase Ⅲ comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer [J]. J Clin Oncol, 2000,18(19):3390-3399.

共引文献44

四川肿瘤防治
2005年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部